Checchi Capital Advisers LLC Has $1.22 Million Stock Holdings in Elevance Health, Inc. (NYSE:ELV)

Checchi Capital Advisers LLC boosted its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 3.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,589 shares of the company’s stock after purchasing an additional 85 shares during the period. Checchi Capital Advisers LLC’s holdings in Elevance Health were worth $1,221,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in ELV. Sanders Capital LLC lifted its position in shares of Elevance Health by 1.4% during the 3rd quarter. Sanders Capital LLC now owns 4,261,976 shares of the company’s stock worth $1,855,750,000 after buying an additional 58,013 shares during the period. Baillie Gifford & Co. raised its stake in Elevance Health by 0.9% during the fourth quarter. Baillie Gifford & Co. now owns 3,087,904 shares of the company’s stock worth $1,456,132,000 after acquiring an additional 27,986 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Elevance Health by 1.7% during the third quarter. Morgan Stanley now owns 2,784,714 shares of the company’s stock valued at $1,212,521,000 after acquiring an additional 46,322 shares during the period. Northern Trust Corp grew its holdings in shares of Elevance Health by 2.4% in the 3rd quarter. Northern Trust Corp now owns 2,416,459 shares of the company’s stock worth $1,052,175,000 after purchasing an additional 57,098 shares during the last quarter. Finally, Artisan Partners Limited Partnership increased its position in shares of Elevance Health by 7.2% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,379,046 shares of the company’s stock worth $1,035,884,000 after purchasing an additional 160,524 shares in the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Trading Down 0.1 %

Shares of Elevance Health stock traded down $0.41 on Monday, hitting $538.77. 951,678 shares of the company’s stock traded hands, compared to its average volume of 1,034,380. The firm’s 50-day moving average price is $516.71 and its two-hundred day moving average price is $492.06. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.37 and a quick ratio of 1.37. The stock has a market capitalization of $125.22 billion, a PE ratio of 20.36, a price-to-earnings-growth ratio of 1.19 and a beta of 0.79. Elevance Health, Inc. has a one year low of $412.00 and a one year high of $543.13.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Thursday, April 18th. The company reported $10.64 EPS for the quarter, beating analysts’ consensus estimates of $10.54 by $0.10. Elevance Health had a return on equity of 20.62% and a net margin of 3.64%. The business had revenue of $42.27 billion during the quarter, compared to the consensus estimate of $42.49 billion. During the same quarter in the prior year, the company posted $9.46 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. On average, research analysts expect that Elevance Health, Inc. will post 37.26 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 25th. Investors of record on Monday, June 10th will be paid a dividend of $1.63 per share. This represents a $6.52 annualized dividend and a yield of 1.21%. The ex-dividend date is Monday, June 10th. Elevance Health’s payout ratio is 24.64%.

Analyst Ratings Changes

ELV has been the topic of a number of recent analyst reports. Barclays boosted their price target on shares of Elevance Health from $584.00 to $621.00 and gave the company an “overweight” rating in a research report on Friday, April 19th. StockNews.com downgraded Elevance Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 25th. UBS Group boosted their price objective on Elevance Health from $585.00 to $605.00 and gave the stock a “buy” rating in a research note on Friday, April 19th. Royal Bank of Canada lifted their price target on Elevance Health from $574.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, April 19th. Finally, Truist Financial reiterated a “buy” rating and set a $600.00 target price (up from $580.00) on shares of Elevance Health in a research report on Friday, April 19th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, Elevance Health presently has a consensus rating of “Moderate Buy” and an average price target of $587.42.

Insider Activity at Elevance Health

In other Elevance Health news, EVP Felicia F. Norwood sold 14,111 shares of the stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $533.74, for a total value of $7,531,605.14. Following the sale, the executive vice president now directly owns 31,460 shares in the company, valued at $16,791,460.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.29% of the company’s stock.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.